These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 37268223)

  • 1. 4CMenB sustained vaccine effectiveness against invasive meningococcal B disease and gonorrhoea at three years post programme implementation.
    Wang B; Giles L; Andraweera P; McMillan M; Almond S; Beazley R; Mitchell J; Ahoure M; Denehy E; Flood L; Marshall H
    J Infect; 2023 Aug; 87(2):95-102. PubMed ID: 37268223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control study.
    Wang B; Giles L; Andraweera P; McMillan M; Almond S; Beazley R; Mitchell J; Lally N; Ahoure M; Denehy E; Koehler A; Flood L; Marshall H
    Lancet Infect Dis; 2022 Jul; 22(7):1011-1020. PubMed ID: 35427492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 4CMenB journey to the 10-year anniversary and beyond.
    Abitbol V; Martinón-Torres F; Taha MK; Nolan T; Muzzi A; Bambini S; Borrow R; Toneatto D; Serino L; Rappuoli R; Pizza M
    Hum Vaccin Immunother; 2024 Dec; 20(1):2357924. PubMed ID: 38976659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Public health impact and cost-effectiveness of gonorrhoea vaccination: an integrated transmission-dynamic health-economic modelling analysis.
    Whittles LK; Didelot X; White PJ
    Lancet Infect Dis; 2022 Jul; 22(7):1030-1041. PubMed ID: 35427491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of a serogroup B outer membrane vesicle meningococcal vaccine against gonorrhoea: a retrospective observational study.
    Abara WE; Bernstein KT; Lewis FMT; Schillinger JA; Feemster K; Pathela P; Hariri S; Islam A; Eberhart M; Cheng I; Ternier A; Slutsker JS; Mbaeyi S; Madera R; Kirkcaldy RD
    Lancet Infect Dis; 2022 Jul; 22(7):1021-1029. PubMed ID: 35427490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccine effectiveness and impact of meningococcal vaccines against gonococcal infections: A systematic review and meta-analysis.
    Wang B; Mohammed H; Andraweera P; McMillan M; Marshall H
    J Infect; 2024 Sep; 89(3):106225. PubMed ID: 38986746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A re-assessment of 4CMenB vaccine effectiveness against serogroup B invasive meningococcal disease in England based on an incidence model.
    Argante L; Abbing-Karahagopian V; Vadivelu K; Rappuoli R; Medini D
    BMC Infect Dis; 2021 Dec; 21(1):1244. PubMed ID: 34895161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup B
    Mulhall RM; Bennett D; Cunney R; Borrow R; Lucidarme J; Findlow J; Jolley KA; Bray J; Maiden MCJ; Moschioni M; Serino L; Stella M; Medini D
    mSphere; 2018 Aug; 3(4):. PubMed ID: 30135218
    [No Abstract]   [Full Text] [Related]  

  • 9. Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study.
    Parikh SR; Andrews NJ; Beebeejaun K; Campbell H; Ribeiro S; Ward C; White JM; Borrow R; Ramsay ME; Ladhani SN
    Lancet; 2016 Dec; 388(10061):2775-2782. PubMed ID: 28100432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the effectiveness of the 4CMenB vaccine against invasive meningococcal disease and gonorrhoea in an infant, child and adolescent program: protocol.
    Marshall HS; Andraweera PH; Wang B; McMillan M; Koehler AP; Lally N; Almond S; Denehy E; A'Houre M; Giles LC; Flood L
    Hum Vaccin Immunother; 2021 May; 17(5):1450-1454. PubMed ID: 33428528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 'Be on the TEAM' Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents.
    Carr J; Plested E; Aley P; Camara S; Davis K; MacLennan JM; Gray S; Faust SN; Borrow R; Christensen H; Trotter C; Maiden MCJ; Finn A; Snape MD;
    BMJ Open; 2020 Oct; 10(10):e037358. PubMed ID: 33093030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling the public health impact of different meningococcal vaccination strategies with 4CMenB and MenACWY versus the current toddler MenACWY National Immunization Program in Chile.
    Graña MG; Cavada G; Vasquez M; Shen J; Maervoet J; Klint J; Gómez JA
    Hum Vaccin Immunother; 2021 Dec; 17(12):5603-5613. PubMed ID: 34890520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Timing of meningococcal vaccination with 4CMenB (Bexsero®) in children with invasive meningococcal group B (MenB) disease in England.
    Ladhani SN; Campbell H; Amin-Chowdhury Z; Lucidarme J; Borrow R; Ramsay ME
    Vaccine; 2022 Mar; 40(10):1493-1498. PubMed ID: 35148913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of meningococcal serogroup B disease in children after implementation of routine infant 4CMenB vaccination in England: an active, prospective, national surveillance study.
    Mensah AA; Campbell H; Clark SA; Ribeiro S; Lucidarme J; Bai X; Borrow R; Ladhani SN
    Lancet Child Adolesc Health; 2023 Mar; 7(3):190-198. PubMed ID: 36736341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in England.
    Ladhani SN; Andrews N; Parikh SR; Campbell H; White J; Edelstein M; Bai X; Lucidarme J; Borrow R; Ramsay ME
    N Engl J Med; 2020 Jan; 382(4):309-317. PubMed ID: 31971676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Four-Component Recombinant Protein-Based Vaccine Effectiveness Against Serogroup B Meningococcal Disease in Italy.
    Lodi L; Barbati F; Amicizia D; Baldo V; Barbui AM; Bondi A; Costantino C; Da Dalt L; Ferrara L; Fortunato F; Guarnieri V; Icardi G; Indolfi G; Martinelli D; Martini M; Moriondo M; Nieddu F; Peroni DG; Prato R; Ricci S; Russo F; Tirelli F; Vitale F; Ladhani SN; Azzari C;
    JAMA Netw Open; 2023 Aug; 6(8):e2329678. PubMed ID: 37594762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An open-label randomised controlled trial evaluating the efficacy of a meningococcal serogroup B (4CMenB) vaccine on Neisseria gonorrhoeae infection in gay and bisexual men: the MenGO study protocol.
    Thng C; Semchenko EA; Hughes I; O'Sullivan M; Seib KL
    BMC Public Health; 2023 Mar; 23(1):607. PubMed ID: 36997957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of a meningococcal group B vaccine (4CMenB) in populations at high risk of gonorrhoea in the UK.
    Ladhani SN; White PJ; Campbell H; Mandal S; Borrow R; Andrews N; Bhopal S; Saunders J; Mohammed H; Drisdale-Gordon L; Callan E; Sinka K; Folkard K; Fifer H; Ramsay ME
    Lancet Infect Dis; 2024 Sep; 24(9):e576-e583. PubMed ID: 38521080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world implementation of 4-component meningococcal serogroup B vaccine (4CMenB): implications for clinical practices.
    Sohn WY; Tahrat H; Novy P; Bekkat-Berkani R
    Expert Rev Vaccines; 2022 Mar; 21(3):325-335. PubMed ID: 35068299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First statewide meningococcal B vaccine program in infants, children and adolescents: evidence for implementation in South Australia.
    Marshall HS; Lally N; Flood L; Phillips P
    Med J Aust; 2020 Feb; 212(2):89-93. PubMed ID: 31909501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.